EDGEWISE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [______ __, 20__], and is between Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 11,627,907 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 14th, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,627,907 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,744,186 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 21,818,182 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 19th, 2024 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 21,818,182 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Shares”). The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
March 3, 2021Employment Letter Agreement • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
LEASE FOR PREMISES LOCATED AT JENNIE SMOLY CARUTHERS BIOTECHNOLOGY BUILDING UNIVERSITY OF COLORADO BOULDER 3415 COLORADO AVENUE, BOULDER, COLORADO 80309 BY AND BETWEEN EDGEWISE THERAPEUTICS, INC., A DELAWARE CORPORATION AS TENANT AND THE REGENTS OF...Lease Agreement • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
THIS LEASE AGREEMENT (“Lease”) is made by and between Landlord and Tenant hereinafter named. In consideration of the respective covenants, obligations, and agreements of the parties set forth herein, the legal sufficiency of which is acknowledged by each of the undersigned, Landlord and Tenant agree as follows:
Edgewise Therapeutics, Inc. Common stock SALES AGREEMENTCommon Stock Sales Agreement • April 1st, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Edgewise Therapeutics, Inc. Common stock SALES AGREEMENTCommon Stock Sales Agreement • May 10th, 2024 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), as follows:
RESTRICTED STOCK UNIT AGREEMENTEquity Incentive Plan • May 11th, 2023 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Unless otherwise defined herein, the terms defined in the Edgewise Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, and all other exhibits, appendices, and addenda attached hereto (the “Award Agreement”).
EDGEWISE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 18th, 2020 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of December 3, 2020 (the “Effective Date”), by and among Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (each, an “Investor” and collectively, the “Investors”).
